Moderna, Inc. (MRNA)
NASDAQ: MRNA · Real-Time Price · USD
24.73
-0.46 (-1.85%)
Apr 17, 2025, 4:00 PM EDT - Market closed
Moderna Employees
Moderna had 5,800 employees as of December 31, 2024. The number of employees increased by 200 or 3.57% compared to the previous year.
Employees
5,800
Change (1Y)
200
Growth (1Y)
3.57%
Revenue / Employee
n/a
Profits / Employee
n/a
Market Cap
9.56B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 5,800 | 200 | 3.57% |
Dec 31, 2023 | 5,600 | 1,700 | 43.59% |
Dec 31, 2022 | 3,900 | 1,200 | 44.44% |
Dec 31, 2021 | 2,700 | 1,400 | 107.69% |
Dec 31, 2020 | 1,300 | 470 | 56.63% |
Dec 31, 2019 | 830 | 70 | 9.21% |
Dec 31, 2018 | 760 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novartis AG | 75,883 |
MRNA News
- 9 days ago - Moderna to Report First Quarter 2025 Financial Results on Thursday, May 1, 2025 - Accesswire
- 12 days ago - Moderna to Showcase Extensive Infectious Disease Research at ESCMID 2025 - Accesswire
- 16 days ago - Trump's Tariffs Could Blow Up Big Pharma's Tax Shelter - WSJ
- 17 days ago - Trump's tariffs are a new challenge for Big Pharma. Here are the best positioned stocks - CNBC
- 18 days ago - S&P 500 Gains and Losses Today: Moderna Stock Plunges After Resignation of FDA Vaccine Official - Investopedia
- 18 days ago - S&P 500 recoups losses, Dow rises as volatile March ends; Newsmax surges, Moderna tanks - Invezz
- 18 days ago - Vaccine stocks tumble: Moderna, Novavax, Pfizer fall after top FDA official resigns over RFK Jr. anti-vax views - Fast Company
- 18 days ago - Biotech stocks plunge as FDA's Peter Marks resigns over RFK Jr. dispute, Moderna and Beam Therapeutics hit hard - Invezz